



(19) Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 669 324 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art.
158(3) EPC

(21) Application number: 94926386.7

(61) Int. Cl.⁶: **C07D 239/94, A61K 31/505**

(22) Date of filing: **12.09.94**

(86) International application number:
PCT/JP94/01504

(87) International publication number:
WO 95/07267 (16.03.95 95/12)

(30) Priority: **10.09.93 JP 248615/93**

Inventor: **KODAMA, Kohtaro**

(43) Date of publication of application:
30.08.95 Bulletin 95/35

3-17, Higashi 2-chome

Tsukuba-shi

Ibaraki 305 (JP)

(84) Designated Contracting States:
BE CH DE DK FR GB IT LI NL SE

Inventor: **ISHIHARA, Hiroki**

42-10, Ohaza Midorigaoka

Tsukuba-shi

Ibaraki 305 (JP)

(71) Applicant: **Eisai Co., Ltd.**
6-10, Koishikawa 4-chome
Bunkyo-ku
Tokyo 112-88 (JP)

Inventor: **SAEKI, Takao**

9-6, Matsumaedai 2-chome

Moriyamachi

Kitasouma-gun

Ibaraki 302-01 (JP)

(72) Inventor: **TAKASE, Yasutaka**
19-13, Kasuga 4-chome
Tsukuba-shi
Ibaraki 305 (JP)

Inventor: **SOUDA, Shigeru**

1687-21, Ushikicho

Ushiku-shi

Ibaraki 315 (JP)

Inventor: **WATANABE, Nobuhisa**

23-5-105, Amakubo 2-chome

Tsukuba-shi

Ibaraki 305 (JP)

Inventor: **ADACHI, Hideyuki**

7-18, Chuo 7-chome

Amimachi

Inashiki-gun

Ibaraki 300-03 (JP)

(74) Representative: **Hansen, Bernd, Dr.**

Dipl.-Chem. et al

Hoffmann, Eitlie & Partner,


Patentanwälte,

Arabellastrasse 4

D-81925 München (DE)

(54) **QUINAZOLINE COMPOUND.**

(57) A quinazoline compound represented by general formula (I), which is useful as a medicine having the activity as a calmodulin-dependent cGMP-PDE inhibitor, or a pharmacologically acceptable salt thereof wherein R¹, R², R³, R⁴ and R⁵ represent each independently hydrogen, lower alkyl, etc.; and R⁶ and R⁷ represent each independently hydrogen, carboxyalkyl, etc.



Field of the Invention

The present invention relates to a quinazoline compound exhibiting an excellent activity as a medicine.

5 Background of the Invention and Prior Art

Angina pectoris which is one of ischemic heart diseases has been known as a disease which frequently attacks the aged. Although nitrate compounds, nitrite compounds, calcium antagonists, β -blockers and so forth have been used as therapeutic agents for the disease, they are still insufficiently effective in treating 10 angina pectoris or in preventing the evolution thereof into myocardial infarction. Further, lowering in the age of a patient with an ischemic heart disease and complication of the condition thereof have recently occurred owing to, e.g., increasing the stress by change in life style and complication of society. Therefore, a new type of more excellent medicine has been eagerly expected.

Among the above-mentioned medicines which are now in use, those which are each one of medicines 15 which have been used most frequently and which have been used for the longest time are nitrate compounds and nitrite compounds. And it is presumed that cyclic GMP (hereinafter abbreviated to cGMP), which is one of the cyclic nucleotides known as intracellular second messengers, participates in the action of these medicines. The cGMP is well known to have relaxing activities on vascular smooth muscle and bronchial smooth muscle. Although the action mechanism of these medicines is not always apparent, it is 20 generally believed that these medicines activate guanylate cyclase to thereby accelerate the synthesis of cGMP, thus increasing the activity of cGMP. However, these medicines exhibit poor biological availability and a relatively short reaction time. Further, it has been reported that tolerance occurs, which becomes a clinical problem.

Under these circumstances, the present inventors have started searching and studying to develop a 25 new type of more excellent medicine.

Namely, the present inventors have directed their attention to a cGMP phosphodiesterase (hereinafter abbreviated to cGMP-PDE) inhibiting activity and have extensively studied on compounds exhibiting such an activity for a long time. As the result, they have found that a nitrogen-containing condensed heterocyclic compound which will be described below exhibits such an activity and hence is efficacious against various 30 ischemic heart diseases and the like. Thus, the present invention has been accomplished.

Although literatures disclosing quinazoline derivatives useful as medicines include, e.g., Toku-hyo Hei. 2-502462 and WO9307124, the compounds disclosed therein are different from the compound of the present invention in both structure and function.


35 Disclosure of the Invention

The present invention relates to a quinazoline compound represented by the general formula (I) or a pharmacologically acceptable salt thereof:

40

45

50



(wherein R¹, R², R³, R⁴ and R⁵ may be the same or different from each other and each represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and

R⁶ and R⁷ may be the same or different from each other and each represents a hydrogen atom, a lower alkyl group, a hydroxyalkyl group, a lower alkoxyalkyl group, a cyanoalkyl group, a heteroarylalkyl group, a cycloalkyl group, a cycloalkylalkyl group or a carboxyl alkyl group which may be protected, or

alternatively R⁶ and R⁷ may form a ring together with the nitrogen atom to which they are bonded, this ring optionally having a substituent).

In the general formula (I), the lower alkyl group in the definitions of R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ means a linear or branched alkyl group having 1 to 6 carbon atoms, for examples, methyl, ethyl, n-propyl, n-butyl, 5 isopropyl, isobutyl, 1-methylpropyl, tert-butyl, n-pentyl, 1-ethylpropyl, isoamyl and n-hexyl. The most desirable examples include methyl group and ethyl group.

The lower alkoxy group in the definitions of R¹, R², R³, R⁴ and R⁵ means methoxy group, ethoxy group, propoxy group, butoxy group and the like which are derived from the above lower alkyl groups. Preferable ones include methoxy group and ethoxy group, and particularly preferable one includes methoxy group.

10 The hydroxyalkyl group in the definitions of R⁶ and R⁷ means the one wherein one or, two or more hydroxyl group(s) is(are) bonded to any of the carbon atoms of the lower alkyl group described above.

The lower alkoxyalkyl group in the definitions of R⁶ and R⁷ means the one wherein one or, two or more lower alkoxy group(s) defined above is(are) bonded to any of the carbon atoms of the alkyl group described above.

15 The cyanoalkyl group in the definitions of R⁶ and R⁷ means the one wherein one or, two or more cyano group(s) is(are) bonded to any of the carbon atoms of the lower alkyl group described above.

The heteroarylalkyl group in the definitions of R⁶ and R⁷ means the one wherein one or, two or more heteroaryl group(s) is(are) bonded to any of the carbon atoms of the lower alkyl group described above.

20 The heteroaryl group means a five- to six-membered ring containing one to three nitrogen atom, sulfur atom and/or oxygen atom, and preferable ones include aromatic rings containing one or two nitrogen atoms, such as imidazolyl group, pyridyl group and pyrimidyl group.

The cycloalkyl group in the definitions of R⁶ and R⁷ means the one having 3 to 8 carbon atoms, and preferably ones include those having 5 to 6 carbon atoms.

25 The cycloalkylalkyl group in the definitions of R⁶ and R⁷ means the one wherein the cycloalkyl group defined above is bonded to any of the carbon atoms of the lower alkyl group described above.

The alkyl group constituting the carboxyl alkyl group which may be protected in the definitions of R⁶ and R⁷ has the same meaning as that of the lower alkyl group described above. The carboxyl group in this case may be bonded to any of the carbon atoms of the alkyl group. The protective group for the carboxyl group includes lower alkyl groups such as methyl, ethyl and t-butyl; phenyl-substituted lower alkyl groups 30 wherein the phenyl group may have a substituent, such as p-methoxybenzyl, p-nitrobenzyl, 3,4-dimethoxybenzyl, diphenylmethyl, trityl and phenethyl; halogenated lower alkyl groups such as 2,2,2-trichloroethyl and 2-iodoethyl; lower alkanoyloxy lower alkyl groups such as pivaloyloxymethyl, acetoxyethyl, propionyloxymethyl, butyryloxymethyl, valeryloxymethyl, 1-acetoxyethyl, 2-acetoxyethyl, 1-pivaloyloxyethyl and 2-pivaloyloxyethyl; higher alkanoyloxy lower alkyl groups such as palmitoyloxyethyl, heptadecanoyloxymethyl and 1-palmitoyloxyethyl; lower alkoxy carbonyloxy lower alkyl groups such as methoxycarbonyloxyethyl, 1-butoxycarbonyloxyethyl and 1-(isopropoxycarbonyloxy)ethyl; carboxy lower alkyl groups such as carboxymethyl and 2-carboxyethyl; a heterocyclic group such as 3-phthalidyl; benzyloxy lower alkyl groups which may have a substituent, such as 4-glycyloxybenzyloxyethyl and 4-[N-(t-butoxycarbonyl)-glycyloxy]benzyloxyethyl; a (substituted dioxolene) lower alkyl group such as (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl; a cycloalkyl-substituted lower alkanoyloxy lower alkyl group such as 1-cyclohexylacetoxyethyl; and a cycloalkyloxycarbonyloxy lower alkyl group such as 1-cyclohexyloxycarbonyloxyethyl.

45 Further, they may form various acid amides. They may be any one as far as it is a protective group which can release a carboxyl group by the decomposition thereof *in vivo*. The quinazoline compound of the present invention exhibits its drug efficacy either by decomposing the protective group *in vivo* or as such.

The ring which is formed from the R⁶ and R⁷ together with the nitrogen atom to which they are bonded in the "R⁶ and R⁷ may form a ring together with the nitrogen atom to which they are bonded, this ring optionally forming a substituent" means a five- to six-membered saturated ring. This ring may further contain a nitrogen atom, an oxygen atom or a sulfur atom in addition to the nitrogen atom to which R⁶ and 50 R⁷ are bonded.

55 The substituent in this case means, e.g., a lower alkyl group, a carboxyl group which may be protected, a cyano group, an acyl group, an amino group which may have a substituent, an aryl group which may have a substituent, a heteroaryl group which may have a substituent, an arylalkyl group which may have a substituent, a heteroarylalkyl group which may have a substituent or the group represented by formula =O. Preferable substituents include carboxyl groups which may be protected, and still more preferable one includes a carboxyl group.

The halogen atom in the definitions of R¹, R², R³, R⁴ and R⁵ means fluorine atom, chlorine atom, bromine atom and iodine atom.

The pharmacologically acceptable salt according to the present invention includes inorganic acid salts such as hydrochloride, sulfate, hydrobromide and phosphate; and organic acid salts such as formate, acetate, trifluoroacetate, maleate, fumarate, tartrate, methanesulfonate, benzenesulfonate and toluenesulfonate.


5 Some of the compounds may form hydrates, which also fall within the scope of the present invention, of course.

Desirable examples of the compound of the present invention include quinazoline compounds represented by the following general formula (I') and pharmacologically acceptable salts thereof:

10

15

20



(wherein R¹, R², R³, R⁴ and R⁵ may be the same or different from each other and each represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and

R^{6x} and R^{7x} may be the same or different from each other and each represents a hydrogen atom, a lower alkyl group or a carboxyl alkyl group which may be protected, or alternatively R^{6x} and R^{7x} may form a ring together with the nitrogen atom to which they are bonded, this ring optionally having a substituent).


30 Among them, preferables are those wherein R^{6x} and R^{7x} may be the same or different from each other and each represents a hydrogen atom or a carboxyl alkyl group which may be protected, or those wherein R⁶ and R⁷ form a ring which may have a substituent, together with the nitrogen atom to which they are bonded.

More desirable compounds among the preferable compounds described above include quinazoline compounds represented by the following general formula (Ia) or pharmacologically acceptable salts thereof:

35

40


45



50 (wherein R^{2a}, R^{3a} and R^{4a} may be the same or different from each other and each represents a halogen atom or a lower alkoxy group; and

R^{6a} and R^{7a} may be the same or different from each other and each represents a hydrogen atom, a lower alkyl group or a carboxyl alkyl group which may be protected, or alternatively R^{6a} and R^{7a} may form a ring together with the nitrogen atom to which they are bonded, this ring optionally having a substituent).

55 Further, the most desirable compounds among the compounds of the present invention include quinazoline compounds represented by the following general formula (Ib) or pharmacologically acceptable salts thereof:





15 (wherein R^{6b} and R^{7b} may be the same or different from each other and each represents a hydrogen atom, a n-propyl group or a carboxypropyl group which may be protected, or alternatively R^{6b} and R^{7b} may form a six-membered ring together with the nitrogen atom to which they are bonded, this ring optionally having a substituent).

20 Compounds wherein R^{6b} and R^{7b} form a piperidine ring together with the nitrogen atom to which they are bonded are preferable, and compounds wherein this piperidine ring has a carboxyl group which may be protected at the 4-position thereof are the most preferable.

Main processes for the preparation of the compound of the present invention will now be described.

Preparation process 1

25 The compound represented by the general formula (I) can be prepared by the following process.



(wherein R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ each has the meaning described above; and X and X' may be the same or different from each other and each means a halogen atom).

(1st step)

5

That is, it is a condensation reaction according to a conventional process.

Although it is preferable to use an alcoholic solvent such as isopropyl alcohol, an etheric solvent such as tetrahydrofuran, or dimethylformamide as the reaction solvent, any organic solvent inert to the reaction can be used.

When the reaction is made to proceed in the presence of a tertiary amine such as triethylamine under reflux by heating with the removal of formed hydrochloric acid, still preferable results can be attained.

(2nd step)

15 It is a reaction which comprises condensing the compound (VIII) obtained in the 1st step with a compound represented by the general formula R^5-H by a conventional process.


Although it is preferable to use an alcoholic solvent such as isopropyl alcohol, an etheric solvent such as tetrahydrofuran, or dimethylformamide as the reaction solvent, any organic solvent inert to the reaction can be used.

20 In this step, it is preferable that the reaction is conducted under reflux by heating in the presence of an organic base such as triethylamine, pyridine and ethyldiisopropylamine; an inorganic base such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, sodium hydride and sodium hydroxide; an alkoxide such as sodium methoxide and potassium t-butoxide; or the like.


25 Preparation process 2

When R^1 , R^3 or R^4 in the general formula (I) is a hydrogen atom, they can be prepared also by the following process.


30



40



50



(wherein R^2 , R^5 , R^6 and R^7 each has the meaning described above; and Y means a halogen atom).

(1st step)

30 That is, it is a reaction which comprises obtaining a compound (X) by treating a halogenated benzamide derivative with a compound corresponding to the desired compound in a solvent in the presence of a base at a temperature ranging from room temperature to the boiling point of the solvent.

Tetrahydrofuran, N,N-dimethylformamide, N-methylpyrrolidone or the like is preferably used as the solvent, though any one, which is inert to this reaction, may be used.

35 Preferable examples of the base include potassium carbonate, hydrides of alkali metals and alkaline earth metals such as lithium hydride and calcium hydride; alkoxides such as potassium t-butoxide and sodium ethoxide; sodium amide and the like.

(2nd step)

Although the reaction is generally conducted under heating, the reaction proceeds sufficiently even at room temperature. Preferable examples of the dehydrating reagent include trifluoroacetic anhydride, thionyl chloride, chlorosulfonyl isocyanate, p-toluenesulfonyl chloride, phosphorus pentachloride, phosphorus oxychloride and the like.

Preferable examples of the reaction solvent include etheric solvents such as tetrahydrofuran and dioxane, acetonitrile, N,N-dimethylformamide, triethylamine, pyridine and the like, though any one, which is inert to the reaction, can be used.

50

That is, it is a step which comprises obtaining an aniline derivative represented by the general formula

55 (XII) by reducing the nitrobenzene derivative obtained in the 2nd step.
It is preferable that the reaction is conducted in a polar solvent, for example, water or an alcoholic

The reaction is generally made to proceed under the acidic condition with acetic acid or hydrochloric acid.

The reaction temperature ranges from room temperature to the refluxing temperature of the solvent.

(4th step)

5 That is, it is a process which comprises obtaining a compound represented by the general formula (XIII) by heating in ethyl orthoformate in the presence of an acid such as trifluoroacetic acid, p-toluenesulfonic acid and concentrated hydrochloric acid.

(5th step)

10 That is, it is a reaction which comprises condensing the compound (XIII) obtained in the 4th step with an amine corresponding to the desired compound through ring closure by a conventional process.

As the reaction solvent, alcoholic ones such as methanol and ethanol can be used. The reaction temperature is preferably around 50 °C, though it may range from room temperature to the boiling point of 15 the solvent.

(6th step)

20 It is a reaction which comprises obtaining an objective compound (I-2) by heating the compound (XIV) obtained in the 5th step in a solvent.

The preferable reaction solvents include alcoholic solvents such as methanol and ethanol, though any solvent inert to the reaction can be used.

Further, more desirable results can be obtained when the reaction is conducted in the presence of an alkali such as aqueous sodium hydroxide and potassium carbonate.

25 The compounds obtained by the above processes can be converted into salts by a conventional process such as the addition of sodium hydroxide, potassium hydroxide, methanesulfonyl chloride or the like.

Preparation process A

30 Among the starting compounds (VII) to be used in the preparation of the compound represented by the general formula (I), the compound (VII') wherein R¹, R³ and R⁴ are hydrogen atoms can be prepared by the following process.


35

40

45

50

55



(in a series of the formulas, R², X and X' each has the meaning described above; and Z means a halogen atom).

30 (1st step)

That is, it is a reaction which comprises obtaining a compound (XVI) by treating a benzene derivative with a compound corresponding to the desired compound in a solvent in the presence of a base at a temperature ranging from room temperature to the boiling point of the solvent.

35 Tetrahydrofuran, N,N-dimethylformamide, N-methylpyrrolidone and the like are preferably used as the solvent, though any solvent inert to the reaction can be used.

Preferable examples of the base include potassium carbonate; hydrides of alkali metals and alkaline earth metals such as lithium hydride and calcium hydride; alkoxides such as potassium t-butoxide and sodium ethoxide; sodium amide and the like.

40

(2nd step)

That is, it is a step which comprises obtaining a compound (XVII) from the compound (XVI) through ring closure by a conventional process. For example, a process which comprises reacting a urea derivative with the compound (XVI) to effect ring closure, and the like may be cited.

The reaction temperature in this case is preferably about 170 to 190 °C, and preferable examples of the reaction solvent include N-methylpyrrolidone and the like, though any organic solvent inert to the reaction can be used.

50 (3rd step)

That is, it is a halogenation reaction. This step can be conducted by a conventional process, and, for example, a process which comprises refluxing in the presence of phosphorus pentachloride and phosphorus oxychloride or in the presence of phosphorus oxychloride by heating under stirring to effect chlorination, and the like can be cited.

Pharmacological Experimental Example will now be described to illustrate the usefulness of the compound of the present invention in detail.

Pharmacological Experimental ExampleStudy on enzyme-inhibitory activity with calmodulin-dependent cGMP-phosphodiesterase obtained from swine aorta

5

1. Experimental method

10

The enzyme activity of calmodulin-dependent cGMP-phosphodiesterase (hereinafter referred to CaM-PDE) prepared from swine aorta was determined according to the method of Thompson et al. The enzyme activity was determined in the presence of 1 mM of calcium ion (Ca^{++}) and calmodulin (250 U/ml) by the use of 1 μM of cGMP as the substrate. The compound of the present invention was dissolved in DMSO and added to the reaction liquid. The final concentration of DMSO in the reaction solution was adjusted to 4% or below.

15

The preparation of the CaM-PDE was effected according to the method [Saeki, T. and Saito, I., Isolation of cyclic nucleotide phosphodiesterase isozymes from pig aorta, Biochem. Pharmacol. in press] by the use of swine aorta.

20

2. Experimental results

25

The CaM-PDE inhibitory activity of the compounds of the present invention as determined by the above method are given in Table 1.

Table 1

30

Ex. No.	IC ₅₀	Ex. No.	IC ₅₀
2	0.48	35	1.90
3	2.35	38	7.90
7	4.62	40	0.17
10	53.9	41	0.30
12	3.50	43	0.74
13	2.37	51	4.30
14	1.29	57	11.6
15	3.62	58	2.80
16	1.65	61	1.10
18	0.73	62	0.74
20	0.42	65	10.7
32	6.40	68	4.00

35

40

It is clarified from the Experimental Example described above that the compound of the present invention exhibits an inhibitory activity on PDE, particularly CaM-PDE. Namely, it is clarified that the compound of the present invention exhibits the effect of increasing the *in vivo* concentration of cGMP because it exhibits an inhibitory activity on CaM-PDE. Accordingly, the quinazoline compound, which is the compound of the present invention, is effective in preventing and treating diseases against which a CaM-PDE inhibitory action is efficacious. Examples of such diseases include ischemic heart diseases such as angina pectoris, myocardial infarction, and chronic and acute cardiac failure; pulmonary hypertension accompanied or not accompanied by cor pulmonale; hypertension caused by various factors; peripheral circulatory disturbance; brain circulatory disturbance; cerebral malfunction; allergic diseases such as bronchial asthma, atopic dermatitis and allergic rhinitis; and the like.

45

Further, the compound of the present invention is lowly toxic and highly safe, thus the present invention is valuable also in this sence.

50

When the present invention is used as a medicine for such diseases, it is administered by oral administration or parenteral administration. The dose thereof varies depending upon the extent of symptom; the age, sex, weight and drug sensitivity of a patient; the method, timing and interval of administration; the type of pharmaceutical preparation; the type of a medicine to be administered together therewith; the type of an active ingredient and so forth, and is not particularly limited.

In the oral administration, generally about 0.1 to 1000 mg, still more preferably 1 to 500 mg, per adult a day, is administered in 1 to 3 portions a day.

In the injection, the daily dose is generally about 1 $\mu\text{g}/\text{kg}$ to 3000 $\mu\text{g}/\text{kg}$, preferably about 3 $\mu\text{g}/\text{kg}$ to 1000 $\mu\text{g}/\text{kg}$.

When a solid preparation for oral administration is prepared, a process which comprises adding a filler and, if necessary, a binder, a disintegrator, a lubricant, a color, a corrigent and the like to the basis and then 5 shaping it into a tablet, a coated tablet, a granule, a powder, a capsule or the like, may be cited.

Examples of the filler to be used include lactose, corn starch, sucrose, glucose, sorbitol, crystalline cellulose and silicon dioxide; those of the binder to be used include polyvinyl alcohol, polyvinyl ether, ethylcellulose, methylcellulose, acacia, tragacanth, gelatin, shellac, hydroxypropylcellulose, hydroxypropylmethylcellulose, calcium citrate, dextrin and pectin; those of the lubricant to be used include magnesium 10 stearate, talc, polyethylene glycol, silica and hardened vegetable oil; those of the color to be used include those authorized as pharmaceutical additives; and those of the corrigent to be used include cocoa powder, menthol, aromatic powder, mentha oil, borneol and powdered cinnamon bark. Of course, the tablet and granule may be those having sugar coating or gelatin coating, or those which are suitably coated at need.

When an injection is prepared, a pH regulator, a buffer, a suspending agent, a solubilizing agent, a 15 stabilizer, an isotonizing agent, a preservative and the like are added to the basis at need, followed by forming into an injection for intravenous, subcutaneous or intramuscular administration by a conventional process. If necessary, a freeze-dried product is prepared by a conventional process.

Examples of the suspending agent include methylcellulose, Polysorbate 80, hydroxyethylcellulose, acacia, tragacanth powder, sodium carboxymethylcellulose, polyoxyethylene sorbitan monolaurate and the 20 like.


Examples of the solubilizing agent include polyoxyethylene hardened castor oil, Polysorbate 80, nicotinamide, polyoxyethylene sorbitan monolaurate, macrogol, ethyl ester of castor oil fatty acid and the like.

25 Example

Examples will now be described to facilitate the understanding of the present invention. It is needless to say that the present invention is not limited to them.

30 Example 1

4-(3-Ethoxycarbonylpropyl)amino-6,7,8-trimethoxyquinazoline




1.0 g of ethyl 4-aminobutyrate hydrochloride (6.0 mmol), 2 ml of triethylamine, 10 ml of tetrahydrofuran and 10 ml of 2-propanol were added to 0.50 g (2.0 mmol) of 4-chloro-6,7,8-trimethoxyquinazoline, followed 50 by heating under reflux one whole day and night. The reaction liquid was distilled under reduced pressure to remove the solvent. The obtained residue was purified by silica gel column chromatography (ethyl acetate) and then recrystallized from ethyl acetate/hexane. Thus, 0.49 g (yield 72%) of a white crystal was obtained.

- 55 • Mol. form. $\text{C}_{17}\text{H}_{23}\text{N}_3\text{O}_5$
- Yield 72%
- M.p. 123 to 124 $^{\circ}\text{C}$
- Mass 350 ($\text{M}^+ + 1$)

- NMR δ (CDCl₃):

1.25(3H, t, J = 7.2Hz) 2.10(2H, quintet, J = 6.4Hz) 2.57(2H, t, J = 6.4Hz) 3.68(2H, m) 4.00(3H, s) 4.03(3H, s) 4.11(3H, s) 4.14(2H, q, J = 7.2Hz) 6.56(1H, br-s) 6.86(1H, s) 8.60(1H, s)


5 Example 24-(3-Carboxypropyl)amino-6,7,8-trimethoxyquinazoline

25 5 ml of a 1N aqueous solution of sodium hydroxide was added to a solution of 0.52 g (1.5 mmol) of the 4-(3-ethoxycarbonylpropyl)amino-6,7,8-trimethoxyquinazoline obtained in Example 1 in tetrahydrofuran (5 ml)/ethanol (5 ml), followed by stirring at room temperature one whole day and night. The reaction liquid was neutralized with 5 ml of 1N hydrochloric acid, and then concentrated under reduced pressure. The crystals thus precipitated were recovered by filtration, washed with water, and dried with air. Thus, 0.36 g (yield 74%) of a pale-yellow crystal was obtained.

- Mol. form. C₁₅H₁₉N₃O₅
- Yield 74%
- M.p. 236 to 237 °C (dec.)
- NMR δ (DMSO-d₆):

1.88(2H, quintet, J = 7.2Hz) 2.33(2H, t, J = 7.2Hz) 3.55(2H, m) 3.87(3H, s) 3.91(3H, s) 3.97(3H, s) 7.44(1H, s) 8.04(1H, brt, J = 5.4Hz) 8.35(1H, s)

30 35 The following compounds were obtained in accordance with the processes of Examples 1 and 2.

Example 34-(5-Ethoxycarbonylpentyl)amino-6,7,8-trimethoxyquinazoline

55


- Mol. form. C₁₉H₂₇N₃O₅
- Yield 84%
- M.p. 128 to 129 °C

- Mass 378(M⁺ + 1)
- NMR δ (CDCl₃);
1.25(3H, t, J = 7.2Hz) 1.49(2H, m) 1.67-1.80(4H, m) 2.35(2H, t, J = 7.0Hz) 3.68(2H, dt, J = 6.8, 6.0Hz) 3.99(3H, s) 4.03(3H, s) 4.11(3H, s) 4.12(2H, q, J = 7.2Hz) 5.72(1H, brs) 6.80(1H, s) 8.61(1H, s)

5

Example 44-(5-Ethoxycarbonylpentyl)amino-6-chloroquinazoline

10



15

20

- Mol. form. C₁₆H₂₀ClN₃O₂
- Yield 84%
- M.p. 117 to 118 °C
- Mass 322(M⁺ + 1)
- NMR δ (CDCl₃);
1.27(3H, t, J = 7.2Hz) 1.49(2H, m) 1.68-1.80(4H, m) 2.37(2H, t, J = 7.0Hz) 3.71(2H, dt, J = 6.8, 5.6Hz) 4.18(2H, q, J = 7.2Hz) 6.03(1H, br-s) 7.66(1H, dd, J = 9.2, 2.4Hz) 7.77(1H, d, J = 9.2Hz) 7.82(1, d, J = 2.4Hz) 8.64(1H, s)


30

Example 54-(Ethoxycarbonylmethyl)amino-6,7,8-trimethoxyquinazoline

35

40

45



50

55


- Mol. form. C₁₅H₁₉N₃O₅
- Yield 84%
- M.p. 182 to 183 °C (dec.)
- Mass 322(M⁺ + 1)
- NMR δ (CDCl₃);
1.35(3H, t, J = 7.2Hz) 3.94(3H, s) 4.04(3H, m) 4.11(3H, s) 4.31(2H, q, J = 7.2Hz) 4.40(2H, d, J = 4.8Hz) 6.23(1H, brt, J = 4.8Hz) 6.76(1H, s) 8.61(1H, s)

Example 64-(6-Ethoxycarbonylhexyl)amino-6,7,8-trimethoxyquinazoline

5

10

15



20

- Mol. form. C₂₀H₂₉N₃O₅
- Yield 98%
- M.p. 132 to 133 °C
- Mass 392(M⁺ + 1)
- NMR δ (CDCl₃);
1.25(3H, t, J = 7.2Hz) 1.36-1.51(4H, m) 1.60-1.79(4H, m) 2.31(2H, t, J = 7.2Hz) 3.65(2H, dt, J = 7.2, 5.6Hz) 3.98(3H, s) 4.03(3H, s) 4.12(3H, s) 4.13(2H, q, J = 7.2Hz) 5.54(1H, brs) 6.72(1H, s) 8.62(1H, s)

Example 7


30

4-(2-Ethoxycarbonylethyl)amino-6,7,8-trimethoxyquinazoline

35

40

45



50

- Mol. form. C₁₆H₂₁N₃O₅
- Yield 57%
- M.p. 141 to 142 °C
- Mass 336(M⁺ + 1)
- NMR δ (CDCl₃);
1.28(3H, t, J = 7.2Hz) 2.76(2H, t, J = 6.0Hz) 3.95(2H, q, J = 6.0Hz) 3.98(3H, s) 4.03(3H, s) 4.12(3H, s) 4.18(2H, q, J = 7.2Hz) 6.23(1H, brs) 6.69(1H, s) 8.61(1H, s)


55

Example 84-(4-Ethoxycarbonylbutyl)amino-6,7,8-trimethoxyquinazoline

5

10

15



20


- Mol. form. $C_{18}H_{25}N_3O_5$
- Yield 35%
- M.p. 139 to 140 °C
- Mass 364($M^+ + 1$)
- NMR δ ($CDCl_3$):
 - 1.28(3H, t, $J = 7.2\text{Hz}$) 1.74-1.86(4H, m) 2.44(2H, t, $J = 6.6\text{Hz}$) 3.64(2H, m) 4.00(3H, s) 4.03(3H, s)
 - 4.12(3H, s) 4.16(2H, q, $J = 7.2\text{Hz}$) 6.10(1H, brs) 6.92(1H, s) 8.61(1H, s)

25

Example 9

30

40



45

50

- Mol. form. $C_{21}H_{31}N_3O_5$
- Yield 61%
- M.p. 124 to 125 °C
- Mass 406($M^+ + 1$)
- NMR δ ($CDCl_3$):
 - 1.25(3H, t, $J = 7.0\text{Hz}$) 1.30-1.48(6H, m) 1.63(2H, m) 1.73(2H, m) 2.30(2H, t, $J = 7.4\text{Hz}$) 3.64(2H, dt, $J = 7.2, 5.6\text{Hz}$) 3.98(3H, s) 4.03(3H, s) 4.12(3H, s) 4.12(2H, q, $J = 7.0\text{Hz}$) 5.53(1H, brs) 6.72(1H, s) 8.62-(1H, s)


55

Example 10

4-(5-Carboxypentyl)amino-6-chloroquinazoline

5

10



15

20

- Mol. form. $C_{14}H_{16}ClN_3O_2$
- Yield quantitative
- M.p. 215 to 216 °C
- NMR δ ($CDCl_3$);
1.37(2H, m) 1.57(2H, quintet, $J = 7.4\text{Hz}$) 1.65(2H, quintet, $J = 7.4\text{Hz}$) 2.22(2H, t, $J = 7.2\text{Hz}$) 3.52(2H, dt, $J = 7.2, 5.2\text{Hz}$) 7.68(1H, d, $J = 8.8\text{Hz}$) 7.75(1H, dd, $J = 8.8, 2.4\text{Hz}$) 8.32(1H, brt, $J = 5.2\text{Hz}$) 8.40(1H, d, $J = 2.4\text{Hz}$) 8.46(1H, s) 11.98(1H, br-s)


25 Example 11

4-(Carboxymethyl)amino-6,7,8-trimethoxyquinazoline

30

35

40



50

55


- Mol. form. $C_{13}H_{15}N_3O_5$
- Yield 54%
- M.p. 121 to 123 °C
- NMR δ ($DMSO-d_6$);
3.89(3H, s) 3.92(3H, s) 3.99(3H, s) 4.18(2H, d, $J = 5.6\text{Hz}$) 7.49(1H, s) 8.37(1H, s) 8.47(1H, brt, $J = 5.6\text{Hz}$)

Example 124-(6-Carboxyhexyl)amino-6,7,8-trimethoxyquinazoline

5

10

15



20

- Mol. form. C₁₈H₂₅N₃O₅
- Yield 89%
- M.p. 184 to 185 °C
- NMR δ (DMSO-d₆);
1.28-1.42(4H, m) 1.52(2H, m) 1.64(2H, m) 2.20(2H, t, J = 7.2Hz) 3.51(2H, m) 3.87(3H, s) 3.91(3H, s) 3.97(3H, s) 7.43(1H, s) 7.99(1H, brt, J = 5.6Hz) 8.35(1H, s)


25

Example 134-(2-Carboxyethyl)amino-6,7,8-trimethoxyquinazoline

30

35

40



45

50

- Mol. form. C₁₄H₁₇N₃O₅
- Yield 56%
- M.p. 236 to 237 °C (dec.)
- NMR δ (DMSO-d₆);
2.65(2H, t, J = 7.0Hz) 3.37(2H, dt, J = 7.0, 5.6Hz) 3.88(3H, s) 3.91(3H, s) 3.98(3H, s) 7.43(1H, s) 8.11(1H, brt, J = 5.6Hz) 8.38(1H, s)


55

Example 144-(4-Carboxybutyl)amino-6,7,8-trimethoxyquinazoline

5

10

15



20

- Mol. form. C₁₆H₂₁N₃O₅
- Yield 34%
- M.p. 208 to 209 °C (dec.)
- NMR δ (DMSO-d₆);
1.54-1.72(4H, m) 2.28(2H, t, J = 7.0Hz) 3.54(2H, m) 3.87(3H, s) 3.91(3H, s) 3.97(3H, s) 7.44(1H, s)
8.04(1H, brt, J = 5.6Hz) 8.35(1H, s) 12.01(1H, brs)


25

Example 154-(7-Carboxyheptyl)amino-6,7,8-trimethoxyquinazoline

30

35

40



45

- Mol. form. C₁₉H₂₇N₃O₅
- Yield 74%
- M.p. 180 to 181 (dec.)
- NMR δ (DMSO-d₆);
1.24-1.41(6H, m) 1.51(2H, m) 1.64(2H, m) 2.19(2H, t, J = 7.4Hz) 3.52(2H, m) 3.87(3H, s) 3.91(3H, s) 3.97(3H, s) 7.44(1H, s) 7.99(1H, brt, J = 5.6Hz) 8.35(1H, s) 11.94(1H, brs)

50


55

Example 164-(5-Carboxypentyl)amino-6,7,8-trimethoxyquinazoline

5

10

15



20

- Mol. form. C₁₇H₂₃N₃O₅
- Yield 76%
- M.p. 213 to 214 °C (dec.)
- NMR δ (DMSO-d₆);
1.38(2H, m) 1.57(2H, m) 1.65(2H, m) 2.23(2H, t, J = 7.2Hz) 3.52(2H, dt, J = 7.2, 5.6Hz) 3.88(3H, s) 3.91(3H, s) 3.97(3H, s) 7.44(1H, s) 8.04(1H, brt, J = 5.6Hz) 8.35(1H, s) 11.99(1H, brs)

25


Example 174-[N-(3-Ethoxycarbonylpropyl)-N-methylaminol-6,7,8-trimethoxyquinazoline hydrochloride

30

35

40

• HCl



45

- Mol. form. C₁₈H₂₅N₃O₅ • HCl
- Yield 67%
- M.p. 94 to 96 °C (dec.)
- NMR δ (DMSO-d₆);
1.15(3H, t, J = 7.2Hz) 2.01(2H, m) 2.41(2H, t, J = 7.2Hz) 3.64(3H, br-s) 3.95(2H) 3.96(3H, s) 3.97-(3H, s) 3.99(3H, s) 4.03(2H, q, J = 7.2Hz) 7.45(1H, s) 8.57(1H, s)


55

Example 184-[N-(3-Carboxypropyl)-N-methylaminol]-6,7,8-trimethoxyquinazoline

5

10

15



20

- Mol. form. C₁₆H₂₁N₃O₅
- Yield 87%
- NMR δ (DMSO-d₆);
1.97(2H, quintet, J = 7.2Hz) 2.27(2H, t, J = 7.2Hz) 3.22(3H, s) 3.61(2H, t, J = 7.2Hz) 3.89(3H, s)
3.90(3H, s) 3.96(3H, s) 7.10(1H, s) 8.41(1H, s)

25


Example 194-(4-Ethoxycarbonylpiperidino)-6,7,8-trimethoxyquinazoline

30

35

40

45



50

55

- Mol. form. C₁₉H₂₅N₃O₅
- Yield 88%
- M.p. oily substance
- NMR δ (DMSO-d₆);
1.30(3H, t, J = 7.0Hz) 1.98(2H, m) 2.12(2H, m) 2.63(1H, m) 3.14(2H, m) 3.97(3H, s) 4.06(3H, s)
4.10(2H, m) 4.13(3H, s) 4.19(2H, q, J = 7.0Hz) 6.92(1H, s) 8.73(1H, s)


Example 204-(4-Carboxypiperidino)-6,7,8-trimethoxyquinazoline

5

10

15

20



25

- Mol. form. $C_{17}H_{21}N_3O_5$
- Yield 77%
- M.p. 233 to 234 °C (dec.)
- Mass 348($M^+ + 1$)
- NMR δ (DMSO- d_6):
 - 1.80(2H, m) 1.99(2H, m) 2.59(1H, m) 3.18(2H, m) 3.92(3H, s) 3.93(3H, s) 4.01(3H, s) 4.09(2H, m) 6.69(1H, s) 8.55(1H, s) 12.29(1H, br-s)

Example 21


35

4-(6-Ethoxycarbonylhexyl)amino-6,7,8-trimethoxyquinazoline

40

45

50



- Mol. form. $C_{20}H_{29}N_3O_5$
- Yield 98%
- M.p. 132 to 133 °C
- Mass 392 ($M^+ + 1$)
- NMR δ ($CDCl_3$):
 - 1.25(3H, t, $J = 7.2Hz$) 1.36-1.51(4H, m) 1.60-1.79(4H, m) 2.31(2H, t, $J = 7.2Hz$) 3.65(2H, dt, $J = 7.2,$


5.6Hz) 3.98(3H, s) 4.03(3H, s) 4.12(3H, s) 4.13(2H, q, $J = 7.2\text{Hz}$) 5.54(1H, brs) 6.72(1H, s) 8.62(1H, s)

Example 22

5 4-(5-Ethoxycarbonylpentyl)amino-6-chloroquinazoline

10

15



20

25

- Mol. form. $C_{16}H_{20}ClN_3O_2$
- Yield 84%
- M.p. 117 to 118 °C
- Mass 322 ($M^+ + 1$)
- NMR δ ($CDCl_3$);
 $1.27(3H, t, J = 7.2\text{Hz})$ $1.49(2H, m)$ $1.68-1.80(4H, m)$ $2.37(2H, t, J = 7.0\text{Hz})$ $3.71(2H, dt, J = 6.8, 5.6\text{Hz})$
 $4.18(2H, q, J = 7.2\text{Hz})$ $6.03(1H, brs)$ $7.66(1H, dd, J = 9.2, 2.4\text{Hz})$ $7.77(1H, d, J = 9.2\text{Hz})$ $7.82(1H, d, J = 2.4\text{Hz})$ $8.64(1H, s)$

Example 23


30 4-[N-(3-Ethoxycarbonylpropyl-N-methylamino)-6,7,8-trimethoxyquinazoline hydrochloride

35

40

45

• HCl




- Mol. form. $C_{18}H_{25}N_3O_5 \cdot HCl$
- Yield 67%
- M.p. 94 to 96 °C
- NMR δ ($DMSO-d_6$);
 $1.15(3H, t, J = 7.2\text{Hz})$ $2.01(2H, m)$ $2.41(2H, t, J = 7.2\text{Hz})$ $3.64(3H, brs)$ $3.95(2H, s)$ $3.96(3H, s)$ $3.97(3H, s)$ $3.99(3H, s)$ $4.03(2H, q, J = 7.2\text{Hz})$ $7.45(1H, s)$ $8.57(1H, s)$

55

Example 244-(3-Ethoxycarbonylpropyl)amino-6,8-dimethoxyquinazoline

5



10

15

20

25

- Mol. form. $C_{16}H_{21}N_3O_4$
- Yield 90%
- M.p. 133 to 134 °C
- Mass 320($M^+ + 1$)
- NMR δ ($CDCl_3$):
 - 1.25(3H, t, $J = 7.2\text{Hz}$) 2.10(2H, quintet, $J = 6.4\text{Hz}$) 2.55(2H, t, $J = 6.4\text{Hz}$) 3.69(2H, dt, $J = 6.4, 4.8\text{Hz}$)
 - 3.93(3H, s) 4.00(3H, s) 4.14(2H, q, $J = 7.2\text{Hz}$) 6.49(1H, brs) 6.61(1H, d, $J = 2.4\text{Hz}$) 6.75(1H, d, $J = 2.4\text{Hz}$)
 - 8.59(1H, s)

Example 25


30

4-(3-Ethoxycarbonylpropyl)amino-8-methoxyquinazoline

35

40

45



50

- Mol. form. $C_{15}H_{19}N_3O_3$
- Yield 64%
- M.p. 128 to 129 °C
- Mass 290($M^+ + 1$)
- NMR δ ($CDCl_3$):
 - 1.24(3H, t, $J = 7.2\text{Hz}$) 2.09(2H, quintet, $J = 6.4\text{Hz}$) 2.53(2H, t, $J = 6.4\text{Hz}$) 3.71(2H, dt, $J = 6.4, 5.2\text{Hz}$)
 - 4.04(3H, s) 4.15(2H, q, $J = 7.2\text{Hz}$) 6.44(1H, brs) 7.11(1H, dd, $J = 8.0, 0.8\text{Hz}$) 7.30(1H, dd, $J = 8.0, 0.8\text{Hz}$)
 - 7.4(1H, t, $J = 8.0\text{Hz}$) 8.69(1H, s)


55

Example 264-(3-Ethoxycarbonylpropyl)amino-6-chloroquinazoline

5

10

15



25


- Mol. form. C₁₄H₁₆ClN₃O₂
- Yield 57%
- M.p. 91 to 92 °C
- Mass 294(M⁺ + 1)
- NMR δ (CDCl₃);
1.26(3H, t, J = 7.2Hz) 2.10(2H, quintet, J = 6.4Hz) 2.54(2H, t, J = 6.4Hz) 3.70(2H, dt, J = 6.4, 5.2Hz)
4.18(2H, q, J = 7.2Hz) 6.60(1H, brs) 7.66(1H, dd, J = 9.2, 2.0Hz) 7.76(1H, d, J = 2.0Hz) 7.77(1H, d,,
J = 9.2Hz) 8.63(1H, s)

Example 274-(3-Ethoxycarbonylpropyl)amino-7-chloroquinazoline

30

35

40



50

- Mol. form. C₁₄H₁₆ClN₃O₂
- Yield 36%
- M.p. 90 to 91 °C
- Mass 294(M⁺ + 1)
- NMR δ (CDCl₃);
1.25(3H, t, J = 7.2Hz) 2.09(2H, quintet, J = 6.4Hz) 2.55(2H, t, J = 6.4Hz) 3.70(2H, dt, J = 6.4, 4.8Hz)
4.16(2H, q, J = 7.2Hz) 6.74(1H, brs) 7.42(1H, dd, J = 8.8, 2.0Hz) 7.71(1H d, J = 8.8Hz) 7.81(1H, d,,
J = 2.0Hz) 8.62(1H, s)


55

Example 284-(Carboxymethyl)amino-6,7,8-trimethoxyquinazoline

5

10

15



20

- Mol. form. C₁₃H₁₅N₃O₅
- Yield 54%
- M.p. 121 to 123 °C
- Mass 294(M⁺ + 1)
- NMR δ (DMSO-d₆):
3.89(3H, s) 3.92(3H, s) 3.99(3H, s) 4.18(2H, d, J = 5.6Hz) 7.49(1H, s) 8.37(1H, s) 8.47(1H, brt, J = 5.6Hz)

25

Example 29


30

4-(6-Carboxyhexyl)amino-6,7,8-trimethoxyquinazoline

35

40

45



50

- Mol. form. C₁₈H₂₅N₃O₅
- Yield 89%
- M.p. 184 to 185 °C
- Mass 364(M⁺ + 1)
- NMR δ (DMSO-d₆):
1.28-1.42(4H, m) 1.52(2H, m) 1.64(2H, m) 2.20(2H, t, J = 7.2Hz) 3.51(2H, m) 3.87(3H, s) 3.91(3H, s) 3.97(3H, s) 7.43(1H, s) 7.99(1H, brt, J = 5.6Hz) 8.35(1H, s)


55

Example 304-[N-(3-Carboxypropyl)-N-methylaminol-6,7,8-trimethoxyquinazoline

5

10

15



20

- Mol. form. C₁₆H₂₁N₃O₅
- Yield 87%
- M.p. 133 to 135 °C
- NMR δ (DMSO-d₆);
1.97(2H, quintet, J = 7.2Hz) 2.27(2H, t, J = 7.2Hz) 3.22(3H, s) 3.61(2H, t, J = 7.2Hz) 3.89(3H, s)
3.90(3H, s) 3.96(3H, s) 7.10(1H, s) 8.41(1H, s)


25

Example 314-(3-Carboxypropyl)amino-6,8-dimethoxyquinazoline

30

35

40



45

50

- Mol. form. C₁₄H₁₇N₃O₄
- Yield 51%
- M.p. 217 to 218 °C (dec.)
- NMR δ (DMSO-d₆);
1.89(2H, quintet, J = 7.2Hz) 2.33(2H, t, J = 7.2Hz) 3.55(2H, dt, J = 7.2, 5.6Hz) 3.88(3H, s) 3.89(3H, s) 6.83(1H, d, J = 2.4Hz) 7.17(1H, d, J = 2.4Hz) 7.99(1H, brt, J = 5.6Hz) 8.31(1H, s)


55

Example 324-(4-Cyanobutyl)amino-6,7,8-trimethoxyquinazoline

5

10

15



20

- Mol. form. $C_{16}H_{20}N_4O_3$
- Yield 94%
- M.p. 160 to 161 °C
- Mass 317 ($M^+ + 1$)
- NMR δ (DMSO-d₆):
 - 1.81(2H, m) 1.94(2H, m) 2.47(2H, t, $J = 6.8\text{Hz}$) 3.75(2H, dt, $J = 6.8, 6.0\text{Hz}$) 4.00(3H, s) 4.03(3H, s)
 - 4.11(3H, s) 5.91(1H, brs) 6.82(1H, s) 8.60(1H, s)

25


Example 33

30

4-(5-Cyanopentyl)amino-6,7,8-trimethoxyquinazoline

35

40



45

50

- Mol. form. $C_{17}H_{22}N_4O_3$
- Yield 75%
- M.p. 155 to 156 °C
- Mass 331 ($M^+ + 1$)
- NMR δ (DMSO-d₆):
 - 1.60-1.80(6H, m) 2.40(2H, t, $J = 7.0\text{Hz}$) 3.70(2H, dt, $J = 7.0, 5.6\text{Hz}$) 4.00(3H, s) 4.03(3H, s) 4.11(3H, s) 6.00(1H, brs) 6.84(1H, s) 8.60(1H, s)


55

Example 344-(2-Hydroxyethyl)amino-6,7,8-trimethoxyquinazoline

5

10

15




25

Example 354-(3-Hydroxypropyl)amino-6,7,8-trimethoxyquinazoline

30

35

40



45

50

55

- Mol. form. $C_{13}H_{17}N_3O_4$
- Yield 80%
- M.p. 183 to 185 °C
- Mass 280 ($M^+ + 1$)
- NMR δ ($CDCl_3$);
3.78(2H, m) 3.88(2H, m) 3.99(3H, s) 4.03(3H, s) 4.10(3H, s) 7.10(1H, brs) 7.13(1H, s) 8.53(1H, s)


- Mol. form. $C_{14}H_{19}N_3O_4$
- Yield 76%
- M.p. 179 to 180 °C
- Mass 294 ($M^+ + 1$)
- NMR δ ($CDCl_3$);
1.89(2H, m) 3.70(2H, t, $J = 5.4\text{Hz}$) 3.85(2H, q, $J = 6.0\text{Hz}$) 3.97(3H, s) 4.03(3H, s) 4.11(3H, s) 6.07-(1H, brs) 6.72(1H, s) 8.56(1H, s)

Example 364-(4-Hydroxybutyl)amino-6,7,8-trimethoxyquinazoline

5

10

15



20

- Mol. form. C₁₅H₂₁N₃O₄
- Yield 74%
- M.p. 171 to 182 °C
- Mass 308 (M⁺ + 1)
- NMR δ (CDCl₃):
 - 1.74(2H, m) 1.88(2H, quintet, J = 6.8Hz) 3.69(2H, dt, J = 6.8, 5.6Hz) 3.80(2H, t, J = 6.0Hz) 3.96(3H, s) 4.03(3H, s) 4.11(3H, s) 6.17(1H, brs) 6.77(1H, s) 8.59(1H, s)

25

Example 37


30

[3-(Imidazol-1-yl)propyl]amino-6,7,8-trimethoxyquinazoline

35

40

45



50

- Mol. form. C₁₇H₂₁N₅O₃
- Yield 82%
- M.p. 192 to 194 °C
- Mass 344 (M⁺ + 1)
- NMR δ (DMSO-d₆):
 - 2.13(2H, quintet, J = 7.0Hz) 3.53(2H, m) 3.88(3H, s) 3.92(3H, s) 3.97(3H, s) 4.13(2H, t, J = 7.0Hz) 7.07(1H, s) 7.35(1H, s) 7.47(1H, s) 8.00(1H, s) 8.20(1H, t, J = 5.4Hz) 8.38(1H, s)

55

Example 386-Chloro-4-[3-(imidazol-1-yl)propyl]aminoquinazoline

5


10

15

20

25

- Mol. form. $C_{14}H_{14}ClN_5$
- Yield 63%
- M.p. 165 to 168 °C
- Mass 288 ($M^+ + 1$)
- NMR δ ($CDCl_3$);
2.24(2H, quintet, $J = 6.4\text{Hz}$) 3.64(2H, q, $J = 6.4\text{Hz}$) 4.14(2H, t, $J = 6.4\text{Hz}$) 7.08(1H, s) 7.09(1H, s) 7.64(1H, dd, $J = 8.8, 2.4\text{Hz}$) 7.73(1H, d, $J = 8.8\text{Hz}$) 7.92(1H, s) 8.06(1H, brs) 8.38(1H, d, $J = 2.4\text{Hz}$) 8.58-(1H, s)

Example 394-Dipropylamino-6,7,8-trimethoxyquinazolinehydrochloride

30


35

40

• HCl

50

- Mol. form. $C_{17}H_{25}N_3O_3 \cdot HCl$
- Yield 78%
- M.p. 169 to 170 °C
- NMR δ ($CDCl_3$);
1.08(6H, t, $J = 7.2\text{Hz}$) 1.92(4H, brm) 3.80(4H, m) 3.97(3H, s) 4.09(3H, s) 4.19(3H, s) 7.02(1H, s) 8.78(1H, s)




55

Example 404-Propylamino-6,7,8-trimethoxyquinazoline

5

10

15



20

- Mol. form. C₁₄H₁₉N₃O₃
- Yield 87%
- NMR δ (CDCl₃);
1.05(3H, t, J = 7.2Hz) 1.77(2H, sextet, J = 7.2Hz) 3.62(2H, dt, J = 7.2, 6.0Hz) 3.98(3H, s) 4.03(3H, s)
4.12(3H, s) 5.50(1H, brs) 6.69(1H, s) 8.63(1H, s)


25

Example 414-Diethylamino-6,7,8-trimethoxyquinazoline hydrochloride

30

35

40



45

50

- Mol. form. C₁₅H₂₁N₃O₃ • HCl
- Yield quantitative
- M.p. 122 to 123 °C
- Mass 292 (M⁺ + 1)
- NMR δ (CDCl₃);
1.51(6H, t, J = 6.8Hz) 3.93(4H, q, J = 6.8Hz) 3.98(3H, s) 4.10(3H, s) 4.20(3H, s) 7.08(1H, s) 8.80(1H, s)


55

Example 424-Diethylamino-6,7-dimethoxyquinazoline hydrochloride

5

10

15



20

- Mol. form. C₁₄H₁₉N₃O₂ • HCl
- Yield 87%
- M.p. 218 to 219 °C
- NMR δ (CDCl₃);
1.51(6H, t, J = 7.2Hz) 3.91(4H, q, J = 7.2Hz) 3.99(3H, s) 4.10(3H, s) 7.25(1H, s) 7.93(1H, s) 8.47(1H, d, J = 2.8Hz)


25

Example 434-Diethylamino-6,8-dimethoxyquinazoline hydrochloride

30

35

40



45

- Mol. form. C₁₄H₁₉N₃O₂ • HCl
- Yield quantitative
- M.p. 160 to 161 °C
- NMR δ (CDCl₃);
1.51(6H, brt) 3.91(3H, s) 3.94(4H, q, J = 7.2Hz) 4.10(3H, s) 6.85(1H, d, J = 2.4Hz) 6.91(1H, d, J = 2.4Hz) 8.82(1H, s)

50

55


Example 44

4-Diethylaminoquinazoline hydrochloride

5

10

15



- Mol. form. $C_{12}H_{15}N_3 \cdot HCl$

20 • Yield 96%

• M.p. 207 to 208 °C

• NMR δ ($CDCl_3$):
 1.52(6H, brs) 3.97(4H, q, $J = 7.2\text{Hz}$) 7.64(1H, ddd, $J = 8.6, 7.2, 1.0\text{Hz}$) 7.90(1H, ddd, $J = 8.4, 7.2, 1.0\text{Hz}$) 7.98(1H, dd, $J = 8.6, 1.0\text{Hz}$) 8.49(1H, dd, $J = 8.4, 1.0\text{Hz}$) 8.59(1H, s)


25 Example 45

4-Diethylamino-8-methoxyquinazoline hydrochloride

30

35

40



- Mol. form. $C_{13}H_{17}N_3O \cdot HCl$

45 • Yield 96%

• M.p. 198 to 199 °C

• NMR δ ($CDCl_3$):
 1.51(6H, brs) 3.96(4H, q, $J = 7.2\text{Hz}$) 4.13(3H, s) 7.29(1H, dd, $J = 7.6, 1.4\text{Hz}$) 7.51(1H, dd, $J = 8.8, 1.4\text{Hz}$) 7.55(1H, dd, $J = 8.8, 7.6\text{Hz}$) 8.93(1H, s)

50


55

Example 467-Chloro-4-diethylaminoquinazoline hydrochloride

5

10

15



20

- Mol. form. C₁₂H₁₄ClN₃•HCl
- Yield 61%
- M.p. 245 to 247 ° C
- NMR δ (CDCl₃);
1.53(6H, brs) 3.95(4H, q, J = 7.2Hz) 7.57(1H, dd, J = 9.2, 2.0Hz) 7.89(1H, d, J = 9.2Hz) 8.51(1H, d, J = 2.0Hz) 8.57(1H, s)

25


Example 476-Chloro-4-diethylaminoquinazoline hydrochloride

30

35

40

45



50

- Mol. form. C₁₂H₁₄ClN₃•HCl
- Yield 66%
- M.p. 219 to 220 ° C
- NMR δ (CDCl₃);
1.64(6H, brs) 3.96(4H, q, J = 7.2Hz) 7.85(1H, dd, J = 8.8, 2.0Hz) 7.93(1H, d, J = 2.0Hz) 8.54(1H, d, J = 8.8Hz) 8.58(1H, s)


55

Example 486-Chloro-4-cyclopentylaminoquinazoline hydrochloride

5

10

15



20

- Mol. form. $C_{13}H_{14}ClN_3 \cdot HCl$
- Yield 87%
- M.p. 239 to 241 ° C
- NMR δ ($CDCl_3$):
 - 1.65-1.74(2H, m) 1.88-2.00(2H, m) 2.00-2.12(2H, m) 2.12-2.22(2H, m) 4.86(1H, sextet, $J = 7.4Hz$)
 - 7.61(1H, dd, $J = 8.8, 2.0Hz$) 8.12(1H, d, $J = 8.8Hz$) 8.55(1H, s) 9.20(1H, d, $J = 2.0Hz$) 9.86(1H, brd, $J = 7.4Hz$)

25


Example 49

30

4-Diethylamino-5,6-dimethoxyquinazoline

35

40



45

50

- Mol. form. $C_{14}H_{19}N_3O_2$
- Yield 70%
- M.p. oily substance
- NMR δ ($CDCl_3$):
 - 1.23(6H, t, $J = 7.0Hz$) 3.61(4H, q, $J = 7.0Hz$) 3.72(3H, s) 3.98(3H, s) 7.49(1H, d, $J = 9.0Hz$) 7.63(1H, d, $J = 9.0Hz$) 8.47(1H, s)


55

Example 504-Diethylamino-2-methyl-6,7,8-trimethoxyquinazoline hydrochloride

5

10

15



20

- Mol. form. C₁₆H₂₃N₃O₃ • HCl
- Yield 85%
- M.p. 186 to 187 °C
- NMR δ (CDCl₃);
1.49(6H, q, J = 7.0Hz) 3.05(3H, s) 3.90(4H, q, J = 7.0Hz) 3.96(3H, s) 4.08(3H, s) 6.98(1H, s)


25

Example 512-Chloro-4-diethylamino-6,7,8-trimethoxyquinazoline

30

35

40



45

- Mol. form. C₁₅H₂₀ClN₃O₃
- Yield 75%
- M.p. 107 to 108 °C
- NMR δ (CDCl₃);
1.40(6H, q, J = 7.2Hz) 3.70(4H, q, J = 7.2Hz) 3.93(3H, s) 4.05(3H, s) 4.08(3H, s) 6.98(1H, s)

50

55

Example 524-Diethylamino-2-(4-hydroxypiperidino)-6,7,8-trimethoxyquinazoline hydrochloride


5

10

15

20

25



- Mol. form. $C_{20}H_{30}N_4O_4 \cdot HCl$
- Yield 53%
- M.p. 77 to 78 ° C
- NMR δ (CD_3OD);
1.48(6H, t, $J = 7.2Hz$) 1.63(2H, m) 2.00(2H, m) 3.59(2H, m) 3.89(4H, q, $J = 7.2Hz$) 3.95(3H, s) 3.97-(1H, m) 4.02(3H, s) 4.06(3H, s) 4.16(2H, m) 7.15(1H, s)

Example 53

30

4-Diethylamino-2-(4-ethoxycarbonylpiperidino)-6,7,8-trimethoxyquinazoline

35

40

45

- Mol. form. $C_{23}H_{34}N_4O_5$
- Yield 36%
- M.p. 80 to 81 ° C
- NMR δ ($CDCl_3$);
1.26(3H, t, $J = 7.2Hz$) 1.34(6H, t, $J = 7.2Hz$) 1.73(2H, m) 1.97(2H, m) 2.55(1H, m) 3.02(2H, m) 3.58-(4H, q, $J = 7.2Hz$) 3.88(3H, s) 4.03(3H, s) 4.08(3H, s) 4.14(2H, q, $J = 7.2Hz$) 4.78(2H, m) 6.88(1H, s)

55

Example 542-(4-Carboxypiperidino)-4-diethylamino-6,7,8-trimethoxyquinazoline


5

10

15

20

25

Example 556-Bromo-4-diethylamino-7,8-dimethoxyquinazoline hydrochloride

30

35

40

45

50

- Mol. form. $C_{21}H_{30}N_4O_5$
- Yield 38%
- NMR δ (DMSO-d₆);
1.31(6H, t, $J = 7.0\text{Hz}$) 1.50(2H, m) 1.87(2H, m) 2.52(1H, m) 3.02(2H, m) 3.58(4H, brs) 3.83(3H, s)
3.85(3H, s) 3.95(3H, s) 4.57(2H, m) 6.89(1H, s) 12.23(1H, brs)

55

Example 564-(4-Carbamoylpiperidino)-6,7,8-trimethoxyquinazoline

5

10

15

20

25

30


35

40

45

50

55



- Mol. form. C₁₇H₂₂N₄O₄

- Yield 81%

- M.p. 165 to 166 °C

- Mass 347 (M⁺ + 1)

- NMR δ (CDCl₃)

2.00-2.10(4H, m) 2.50(1H, m) 3.09(2H, m) 3.97(3H, s) 4.06(3H, s) 4.13(3H, s) 4.20(2H, m) 5.56(1H, brs) 5.64(1H, brs) 6.93(1H, s) 8.73(1H, s)

Example 574-[4-(4-Fluorobenzoyl)piperidinol-6,7,8-trimethoxyquinazoline

5

10

15

20

25

30


- Mol. form. $C_{23}H_{24}FN_3O_4$
- Yield 84%
- M.p. 137 to 138 °C
- Mass 426 ($M^+ + 1$)
- NMR δ ($CDCl_3$)
 - 2.03-2.15(4H, m) 3.21(2H, m) 3.56(1H, m) 3.97(3H, s) 4.07(3H, s) 4.14(3H, s) 4.23(2H, m) 6.95(1H, s) 7.19(2H, m) 8.04(2H, m) 8.75(1H, s)

40

45

50

55



Example 584-[4-(4-Fluoro- α -hydroxybenzyl)piperidinol-6,7,8-trimethoxyquinazoline

5


10

15

20

25

30



35

- Mol. form. $C_{23}H_{26}FN_3O_4$
- Yield 90%
- M.p. 187 to 188 °C
- Mass 428 ($M^+ + 1$)
- NMR δ ($CDCl_3$)
 - 1.42-1.53(2H, m) 1.57-1.68(2H, m) 1.92(1H, m) 2.16(1H, m) 2.92-3.07(2H, m) 3.95(3H, s) 4.05(3H, s) 4.12(3H, s) 4.10-4.30(2H, m) 4.49(1H, d, $J = 7.2\text{Hz}$) 6.90(1H, s) 7.07(2H, m) 7.33(2H, m) 8.70(1H, s)

40

45

50

55

Example 594-(4-Dimethylaminopiperidino)-6,7,8-trimethoxyquinazoline dihydrochloride

5

10

15

20

25

30


35

40

45

50

55



- Mol. form. $C_{18}H_{26}N_4O_3 \cdot 2HCl$
- Yield 55%
- M.p. 197 to 198 °C (dec.)
- Mass 347 ($M^+ + 1$)
- NMR δ ($CDCl_3$)
 - 1.90(2H, m) 2.29(2H, m) 2.73(6H, d, $J = 5.2\text{Hz}$) 3.55(2H, m) 3.66(1H, m) 4.010(3H, s) 4.012(3H, s)
 - 4.03(3H, s) 4.84(2H, m) 7.24(1H, s) 8.70(1H, s) 11.35(1H, brs)

Example 60

4-(4-Piperidinopiperidino)-6,7,8-trimethoxyquinazoline dihydrochloride


5

10

15

20

25



- Mol. form. C₂₁H₃₀N₄O₃ • 2HCl
- Yield 92%
- M.p. 219 to 220 °C (dec.)
- Mass 347 (M⁺ + 1)
- NMR δ (CDCl₃)

1.55(1H, m) 1.82-2.08(7H, m) 2.40(2H, m) 3.05(2H, m) 3.53-3.75(5H, m) 4.06(3H, s) 4.10(3H, s)
4.13(3H, s) 5.05(2H, m) 7.24(1H, s) 8.58(1H, s)

35

40

45

50

55


Example 614-(4-Oxopiperidino)-6,7,8-trimethoxyquinazoline

5

10

15

20



25

- Mol. form. C₁₆H₁₉N₃O₄
- Yield 66%
- M.p. 135 to 136 °C
- Mass 318 (M⁺ + 1)
- NMR δ (CDCl₃)
 - 2.68(4H, t, J = 6.0Hz) 3.98(3H, s) 4.00(4H, t, J = 6.0Hz) 4.08(3H, s) 4.15(3H, s) 6.97(1H, s) 8.77(1H, s)

Example 62

35


4-(4-Hydroxypiperidino)-6,7,8-trimethoxyquinazoline

40

45

50

55




- Mol. form. C₁₆H₂₁N₃O₄

- Yield 83%
- M.p. 150 to 151 °C
- Mass 320 ($M^+ + 1$)
- NMR δ ($CDCl_3$)

5 1.79(2H, m) 2.11(2H, m) 3.33(2H, m) 3.97(3H, s) 3.98-4.08(3H, m) 4.06(3H, s) 4.13(3H, s) 6.92(1H, s) 8.72(1H, s)

Example 63

10 4-Pyrrolidino-6,7,8-trimethoxyquinazoline hydrochloride



30

- Mol. form. $C_{15}H_{19}N_3O_3 \cdot HCl$
- Yield 77%
- M.p. 156 to 157 °C
- Mass 290 ($M^+ + 1$)
- NMR δ ($CDCl_3$)

35 2.12(2H, brs) 2.23(2H, brs) 4.00(2H, brs) 4.03(3H, s) 4.09(3H, s) 4.16(3H, s) 4.29(2H, brs) 7.39(1H, s) 8.64(1H, s)

40

45

50

55


Example 644-Piperidino-6,7,8-trimethoxyquinazoline hydrochloride

5

10

15

20



- Mol. form. $C_{16}H_{21}N_3O \cdot HCl$
- Yield 85%
- M.p. 145 to 146 ° C
- Mass 304 ($M^+ + 1$)
- NMR δ ($CDCl_3$)
 - 1.87(6H, brs) 3.98(3H, s) 4.09(3H, s) 4.11(4H, brt) 4.19(3H, s) 6.95(1H, s) 8.75(1H, s)

Example 654-[4-(2-Pyrimidyl)piperazin-1-yl]-6,7,8-trimethoxyquinazoline


35

40

45

50

55



- Mol. form. $C_{19}H_{22}N_6O_3$

- Yield 86%
- M.p. 157 to 158 °C
- Mass 383 ($M^+ + 1$)
- NMR δ ($CDCl_3$)

5 3.75(4H, m) 3.97(3H, s) 4.06(4H, m) 4.08(3H, s) 4.14(3H, s) 6.57(1H, t, $J = 4.8$ Hz) 6.99(1H, s) 8.37-(2H, d, $J = 4.8$ Hz) 8.76(1H, s)

Example 66


10 4-[4-(2-Pyridyl)piperazin-1-yl]-6,7,8-trimethoxyquinazoline

15

20

25

30



35

- Mol. form. $C_{20}H_{23}N_5O_3$
- Yield 80%
- M.p. 145 to 146 °C
- Mass 382 ($M^+ + 1$)
- NMR δ ($CDCl_3$)

40 3.79(8H, brs) 3.97(3H, s) 4.08(3H, s) 4.14(3H, s) 6.69(1H, ddd, $J = 7.2, 4.8, 0.8$ Hz) 6.75(1H, dt, $J = 8.8, 0.8$ Hz) 7.00(1H, s) 7.55(1H, ddd, $J = 8.8, 7.2, 2.0$ Hz) 8.24(1H, ddd, $J = 4.8, 2.0, 0.8$ Hz) 8.77(1H, s)

45

50

55

Example 67

4-(4-Dimethylaminopiperidino)-6,7,8-trimethoxyquinazoline


5

10

15

20

25



30

- Mol. form. C₁₈H₂₆N₄O₃
- Yield 42%
- M.p. 182 to 184 °C
- Mass 347 (M⁺ + 1)
- NMR δ (CDCl₃)
 - 2.05(2H, m) 2.36(2H, m) 2.82(6H, s) 3.15(2H, m) 3.37(1H, m) 3.98(3H, s) 4.07(3H, s) 4.14(3H, s)
 - 4.36(2H, m) 6.87(1H, s) 8.75(1H, s)

35

Example 68


4-Morpholino-6,7,8-trimethoxyquinazoline hydrochloride

40

45

50

55




- Mol. form. C₁₅H₁₉N₃O₄ • HCl
- Yield 84%

- M.p. 158 to 159 °C
- Mass 306 ($M^+ + 1$)
- NMR δ ($CDCl_3$)

5 3.87(4H, t, $J = 4.4Hz$) 3.99(3H, s) 4.11(3H, s) 4.20(3H, s) 4.24(4H, t, $J = 4.4Hz$) 6.93(1H, s) 8.82(1H, s)

Example 694-(3-Carboxypropyl)amino-6-chloroquinazoline

10




- Mol. form. $C_{12}H_{12}ClN_3O_2$
- Yield 78%
- 25 • M.p. 257 to 258 °C (dec.)
- NMR δ ($DMSO-d_6$):

1.85(2H, quintet, $J = 7.2Hz$) 2.31(2H, t, $J = 7.2Hz$) 3.52(2H, dt, $J = 7.2, 5.2Hz$) 7.67(1H, d, $J = 8.8Hz$)
7.75(1H, dd, $J = 8.8, 2.4Hz$) 8.34(1H, brt, $J = 5.2Hz$) 8.39(1H, d, $J = 2.4Hz$) 8.44(1H, s) 12.07(1H, brs)

Example 704-(3-Carboxypropyl)amino-7-chloroquinazoline

35



- Mol. form. $C_{12}H_{12}N_3O_2$
- Yield 89%
- M.p. 243 to 244 °C (dec.)
- 50 • NMR δ ($DMSO-d_6$):

1.87(2H, quintet, $J = 7.2Hz$) 2.33(2H, t, $J = 7.2Hz$) 3.55(2H, dt, $J = 7.2, 5.6Hz$) 7.67(1H, dd, $J = 8.8, 2.4Hz$) 7.71(1H, d, $J = 2.4Hz$) 8.28(1H, d, $J = 8.8Hz$) 8.44(1H, brt, $J = 5.6Hz$) 8.46(1H, s) 12.09(1H, brs)


55

Example 716-Chloro-4-diethylamino-7,8-dimethoxyquinazoline hydrochloride

5

10

15



20

- Mol. form. $C_{14}H_{18}ClN_3O_2 \cdot HCl$
- Yield 83%
- M.p. 129 to 130 °C (dec.)
- NMR δ ($CDCl_3$);
1.87(2H, quintet, $J = 7.2\text{Hz}$) 2.33(2H, t, $J = 7.2\text{Hz}$) 3.55(2H, dt, $J = 7.2, 5.6\text{Hz}$) 7.67(1H, dd, $J = 8.8, 2.4\text{Hz}$) 7.71(1H, d, $J = 2.4\text{Hz}$) 8.28(1H, d, $J = 8.8\text{Hz}$) 8.44(1H, brt, $J = 5.6\text{Hz}$) 8.46(1H, s) 12.09(1H, brs)


25

Example 726-Bromo-4-diethylamino-7,8-dimethoxyquinazoline hydrochloride

30

35

40



45

- Mol. form. $C_{14}H_{18}BrN_3O_2 \cdot HCl$
- Yield 75%
- M.p. 148 to 149 °C
- NMR δ ($CDCl_3$);
1.50(6H, brs) 3.93(4H, q, $J = 7.0\text{Hz}$) 4.13(3H, s) 4.19(3H, s) 7.94(1H, s) 8.84(1H, s)


50

55

Example 73

4-Diethylamino-7-methoxy-6-methylthioquinazoline hydrochloride

5



10

15

- Mol. form. C₁₄H₁₉N₃OS•HCl
- Yield 67%
- 20 • M.p. 213 to 214 °C
- NMR δ (CDCl₃);
1.51(6H, t, J = 7.0Hz) 2.51(3H, s) 3.92(4H, q, J = 7.0Hz) 4.11(3H, s) 7.55(1H, s) 7.86(1H, s) 8.48(1H, s)


25 **Claims**

1. A quinazoline compound represented by the general formula (I) or a pharmacologically acceptable salt thereof:

30

35

40



(wherein R¹, R², R³, R⁴ and R⁵ may be the same or different from each other and each represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and

R⁶ and R⁷ may be the same or different from each other and each represents a hydrogen atom, a lower alkyl group, a hydroxyalkyl group, a lower alkoxyalkyl group, a cyanoalkyl group, a heteroarylalkyl group, a cycloalkyl group, a cycloalkylalkyl group or a carboxyl alkyl group which may be protected, or alternatively R⁶ and R⁷ may form a ring together with the nitrogen atom to which they are bonded, this ring optionally having a substituent).


2. The quinazoline compound or the pharmacologically acceptable salt thereof as set forth in claim 1, wherein R⁶ and R⁷ form a ring together with the nitrogen atom to which they are bonded, and the ring has, as a substituent, a lower alkyl group, a carboxyl group which may be protected, a cyano group, an acyl group, an amino group which may have a substituent, an aryl group which may have a substituent, a heteroaryl group which may have a substituent, an arylalkyl group which may have a substituent, a heteroarylalkyl group which may have a substituent or a group represented by the formula =O.

3. The quinazoline compound or the pharmacologically acceptable salt thereof as set forth in claim 1, which is represented by the general formula (I''):

5

10

15



(wherein R¹, R², R³, R⁴ and R⁵ may be the same or different from each other and each represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and


R^{6Z} and R^{7Z} may be the same or different from each other and each represents a hydrogen atom or a carboxyl alkyl group which may be protected, or alternatively R^{6Z} and R^{7Z} may form a ring together with the nitrogen atom to which they are bonded, this ring optionally having a substituent).

4. The quinazoline compound or the pharmacologically acceptable salt thereof as set forth in claim 1, which is represented by the general formula (Ia):

30

35

40




(wherein R^{2a}, R^{3a} and R^{4a} may be the same or different from each other and each represents a halogen atom or a lower alkoxy group; and

R^{6a} and R^{7a} may be the same or different from each other and each represents a hydrogen atom, a lower alkyl group or a carboxyl alkyl group which may be protected, or alternatively R^{6a} and R^{7a} may form a ring together with the nitrogen atom to which they are bonded, this ring optionally having a substituent).

5. The quinazoline compound or the pharmacologically acceptable salt thereof as set forth in claim 1, which is represented by the general formula (Ib):

50

55



15 (wherein R^{6b} and R^{7b} may be the same or different from each other and each represents a hydrogen atom, a n-propyl group or a carboxypropyl group which may be protected, or alternatively R^{6b} and R^{7b} may form a six-membered ring together with the nitrogen atom to which they are bonded, this ring optionally having a substituent).

20 6. A preventive and therapeutic agent for diseases against which a phosphodiesterase inhibitory action is efficacious, which comprises a quinazoline compound or a pharmacologically acceptable salt thereof as set forth in claim 1 as an active ingredient.

25 7. A preventive and therapeutic agent for diseases against which a selective inhibitory action on calmodulin-dependent phosphodiesterase is efficacious, which comprises a quinazoline compound or a pharmacologically acceptable salt thereof as set forth in claim 1 as an active ingredient.

30 8. A medicinal composition comprising a therapeutically effective amount of a quinazoline compound or a pharmacologically acceptable salt thereof as set forth in claim 1, and a pharmacologically acceptable filler.

35 9. A use of a quinazoline compound or a pharmacologically acceptable salt thereof as set forth in claim 1 for preparing a medicine for the treatment of diseases against which a phosphodiesterase inhibitory action is efficacious.

10. A method for treating a disease which comprises administering a pharmacologically effective dose of a quinazoline compound or a pharmacologically acceptable salt thereof as set forth in claim 1 to a patient suffering from a disease against which a phosphodiesterase inhibitory action is efficacious.

40

45

50

55

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP94/01504

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl⁶ C07D239/94, A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl⁶ C07D239/94, A61K31/505

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO, A, 9307124 (Eisai Co., Ltd.), April 15, 1993 (15. 04. 93), Claim, example & EP, A, 607439	1-9
X	Farm. Zh. (Kiev), No. 6, (1979) Grin, V.A., et al "Structure and antimicrobial activity of N-(4-quinazolyl)-.alpha.-aminocarboxylic acids and their derivatives"	1, 3, 4, 6-9
P	J. Med. Chem., Vol. 36, No. 24, (1993) Y. Takase, et al "Cyclic GMP Phosphodiesterase Inhibitors. 1. The Discovery of a Nobel Potent Inhibitor, 4-((3,4-(Methylenedioxy)benzyl)amino)-6,7,8- trimethoxyquinazoline", P. 3765-3770	1-9
X	US, A, 4309541 (Ciba-Geigy Corporation, Ardsley, N.Y.), January 5, 1982 (05. 01. 82), EXAMPLE 1, 5, (Family: none)	1, 3-5

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:
 "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 "&" document member of the same patent family

Date of the actual completion of the international search
November 14, 1994 (14. 11. 94)Date of mailing of the international search report
December 6, 1994 (06. 12. 94)Name and mailing address of the ISA/
Japanese Patent Office
Facsimile No.Authorized officer
Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP94/01504

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB, A, 1297595 (Bristol-Myers Company), November 22, 1972 (22. 11. 72), Column of claim & ZA, A, 7100253	1, 3-5
X	JP, A, 1-246264 (Eli Lilly and Co.), October 2, 1989 (02. 10. 89), Claim & EP, A, 326328	1
X	JP, A, 1-226877 (Eli Lilly and Co.), September 11, 1989 (11. 09. 89), Claim & EP, A, 326329	1
X	JP, A, 54-2327 (Sankyo Co., Ltd.), January 9, 1979 (09. 01. 79), Claim, (Family: none)	1
X	JP, A, 50-29582 (Pfizer Corp.), March 25, 1975 (25. 03. 75), Claim & US, A, 3971783	1, 8
X	JP, A, 46-1324 (Annotela), September 20, 1971 (20. 09. 71), Claim & US, A, 3772295	1
X	JP, B1, 46-10543 (Charles Pfizer and Co., Inc.), March 17, 1971 (17. 03. 71), Pages 1 to 2 & GB, A, 1199768	1-5
X	JP, B1, 48-37035 (Sandoz AG.), November 8, 1973 (08. 11. 73), Page 1 & DE, A, 2059164	1-5
X	JP, B1, 47-34717 (Sandoz AG.), September 1, 1972 (01. 09. 72), Page 1 & DE, A, 2009472	1